Actively Recruiting
The Clinical Study on the Treatment of Refractory RA With UTAA91 Injection
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-07-18
24
Participants Needed
1
Research Sites
783 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with refractory moderate - to - severe active rheumatoid arthritis.
CONDITIONS
Official Title
The Clinical Study on the Treatment of Refractory RA With UTAA91 Injection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older with no gender restriction
- Expected survival time of at least 3 months
- Diagnosed with refractory moderate-to-severe active rheumatoid arthritis unresponsive to standard treatment or lacking effective options
- Adequate liver, kidney, and cardiopulmonary function
- No severe psychiatric disorders
- Able to understand the trial and have signed informed consent form
You will not qualify if you...
- History of malignant tumors within 5 years prior to screening, excluding relapsed/refractory autoimmune diseases
- Positive virus or syphilis test results
- Severe cardiac diseases or unstable systemic illnesses
- Active or uncontrolled infections needing systemic treatment within 7 days before administration
- Evidence of central nervous system invasion at screening
- Pregnant or breastfeeding women, or planning pregnancy within 2 years after treatment
- Prior CAR-T therapy or other gene-modified cell therapies before screening
- Participation in other clinical studies within 1 month before screening
- Other conditions judged unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430000
Actively Recruiting
Research Team
Q
Qiubai Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here